ISSN: 1568-0096

Journal Home

Journal Guideline

Current Cancer Drug Targets Q2 Unclaimed

Bentham Science Publishers B.V. United Arab Emirates

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Cancer Drug Targets is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 103. It has an SJR impact factor of 0,65 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,65.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Drug Discovery (Q2) Pharmacology (Q2) Cancer Research (Q3) Oncology (Q3)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,65

SJR Impact factor

103

H Index

76

Total Docs (Last Year)

216

Total Docs (3 years)

5127

Total Refs

602

Total Cites (3 years)

211

Citable Docs (3 years)

2.34

Cites/Doc (2 years)

67.46

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Biomolecules and Therapeutics Q2
PPAR Research Q2
Current Drug Targets Q2
Journal of Gene Medicine Q2
Current Gene Therapy Q2

Compare this journals

Aims and Scope

Best articles by citations

miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents

Molecular Targeting of Liposomal Nano-Particles to Lymphatic System

Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer

Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy

PI-3-Kinase Inhibitors in Colorectal Cancer

Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment

HSV-1 Viral Oncolysis and Molecular Imaging with PET

Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer

The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review

Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges

Editorial (Thematic Issue: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy)

AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1

SHOW MORE ARTICLES

Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer

Author Index To Volume 6

Editorial [ Hot Topic: Oncolytic Virus Therapy (Guest Editor: Hideki Kasuya) ]

Meet Our Editorial Board Member:

Melatonin as a Selective Estrogen Enzyme Modulator

Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin

Silica Nanoparticles as Promising Drug/Gene Delivery Carriers and Fluorescent Nano-Probes: Recent Advances

Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3

Identification of the ZAK-MKK4-JNK-TGFβ Signaling Pathway as a Molecular Target for Novel Synthetic Iminoquinone Anticancer Compound BA-TPQ

Anatomic Site-Related Expression of Cancer-Associated Molecules in Ovarian Carcinoma

Nanotherapy Targeting the Tumor Microenvironment

Costimulation, Coinhibition and Cancer